Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
— Company on track to report topline results early in the second quarter of 2026 — Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomized — No drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reported — Study is no longer screening new participants […]